teva-english-logo-gray-web-5-1
Photo: Courtesy of Teva
18 January 2017Americas

Teva sues Mylan over Copaxone patent infringement

Teva has sued Mylan for alleged patent infringement over Copaxone (glatiramer acetate injection), a treatment for patients with relapsing-remitting forms of multiple sclerosis.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
12 December 2017   Teva has dropped its litigation over two US patents against Mylan, after a district court adopted Mylan’s interpretation of the patents.

More on this story

Big Pharma
12 December 2017   Teva has dropped its litigation over two US patents against Mylan, after a district court adopted Mylan’s interpretation of the patents.

More on this story

Big Pharma
12 December 2017   Teva has dropped its litigation over two US patents against Mylan, after a district court adopted Mylan’s interpretation of the patents.